EUVIMEDEUVIMED entdecken
Open Access

Serum Urate and Recurrent Gout

Natalie McCormick, Chio Yokose, Gregory J Challener, Amit D Joshi, Sruthi Tanikella, Hyon K Choi

JAMA · 06.02.2024 · 331 (5) · 417

DOI: 10.1001/jama.2023.26640 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JAMA, erschienen am 06.02.2024. Verfasst von Natalie McCormick und 5 weiteren Autor:innen. Beteiligte Einrichtung: Rheumatology & Allergy Clinical Epidemiology Research Center, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Bost…. Hauptthemen laut MEDLINE: Gout, Uric Acid. Die Arbeit wurde bisher 49-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance Approximately 12 million adults in the US have a history of gout, but whether serum urate levels can help predict recurrence is unclear.

Objective

To assess associations of a single serum urate measurement with subsequent risk of acute gout flares and subsequent risk of hospitalizations for gout among patients in the UK with a history of gout. Design, Setting, and Participants This retrospective study included patients with a history of gout identified from the UK between 2006 and 2010 who were followed up through Primary Care Linked Data medical record linkage until 2017 and through the Hospital Episode Statistics database until 2020. Exposures Serum urate levels at enrollment. Main Outcome and Measure Rate of recurrent acute gout, ascertained by hospitalization, outpatient, and prescription/procedure records, and adjusted rate ratios using negative binomial regressions.

Results

Among 3613 patients with gout (mean age, 60 years; 3104 [86%] men), 1773 gout flares occurred over a mean follow-up of 8.3 years. Of these, 1679 acute gout flares (95%) occurred in people with baseline serum urate greater than or equal to 6 mg/dL and 1731 (98%) occurred in people with baseline serum urate greater than or equal to 5 mg/dL. Rates of acute gout flares per 1000 person-years were 10.6 for participants with baseline urate levels less than 6 mg/dL, 40.1 for levels of 6.0 to 6.9 mg/dL, 82.0 for levels of 7.0 to 7.9 mg/dL, 101.3 for levels of 8.0 to 8.9 mg/dL, 125.3 for urate levels of 9.0 to 9.9 mg/dL, and 132.8 for levels greater than or equal to 10 mg/dL. Rate ratio of flares were 1.0, 3.37, 6.93, 8.67, 10.81, and 11.42, respectively, over 10 years (1.61 [1.54-1.68] per mg/dL). Rates of hospitalization per 1000 person-years during follow-up were 0.18 for those with baseline serum urate less than 6 mg/dL, 0.97 for serum urate of 6.0 to 6.9 mg/dL, 1.8 for serum urate of 7.0 to 7.9 mg/dL, 2.2 for serum urate of 8.0 to 8.9 mg/dL, 6.7 for serum urate of 9.0 to 9.9 mg/dL, and 9.7 for serum urate greater than or equal to 10 mg/dL. Rate ratios of hospitalization for gout, adjusting for age, sex, and race were 1.0, 4.70, 8.94, 10.37, 33.92, and 45.29, respectively (1.87 [1.57-2.23] per mg/dL). Conclusions and Relevance In this retrospective study of patients with a history of gout, serum urate levels at baseline were associated with the risk of subsequent gout flares and rates of hospitalization for recurrent gout. These findings support using a baseline serum urate level to assess risk of recurrent gout over nearly 10 years of follow-up.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GoutUric AcidFemaleHumansMaleMiddle AgedDatabases, FactualHospitalizationRetrospective StudiesRecurrenceUnited KingdomRisk AssessmentFollow-Up StudiesSymptom Flare Up

Substanzen

Uric Acid

Autor:innen und Institutionen

  • Rheumatology & Allergy Clinical Epidemiology Research Center, Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston.
  • The Mongan Institute, Department of Medicine, Massachusetts General Hospital, Boston.
  • Department of Medicine, Harvard Medical School, Boston, Massachusetts.
  • Arthritis Research Canada, Vancouver, British Columbia, Canada.
  • Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston.
  • Channing Division of Network Medicine, Boston, Massachusetts.

Förderung

  • NIAMS NIH HHS

Zitieren

APA

McCormick, N., Yokose, C., Challener, G. J., Joshi, A. D., Tanikella, S., & Choi, H. K. (2024). Serum Urate and Recurrent Gout. JAMA, 331(5), 417. https://doi.org/10.1001/jama.2023.26640

Vancouver

McCormick N, Yokose C, Challener GJ, Joshi AD, Tanikella S, Choi HK. Serum Urate and Recurrent Gout. JAMA. 2024;331(5):417. doi:10.1001/jama.2023.26640

BibTeX
@article{McCormick2024,
  author = {McCormick, Natalie and Yokose, Chio and Challener, Gregory J and Joshi, Amit D and Tanikella, Sruthi and Choi, Hyon K},
  title = {Serum Urate and Recurrent Gout},
  journal = {JAMA},
  year = {2024},
  volume = {331},
  number = {5},
  pages = {417},
  doi = {10.1001/jama.2023.26640}
}
Kostenlos starten →